Mustang (MBIO) Soars 477% on Data From Rare Blood Cancer Study [Yahoo! Finance]
![Yahoo! Finance](../../../Content/images/providers/Yahoo! Finance.png)
Mustang Bio, Inc. (MBIO)
Last mustang bio, inc. earnings: 11/12 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
mustangbio.com/investor-relations
Company Research
Source: Yahoo! Finance
Data from the study showed that treatment with MB-106 exhibited a favorable safety and efficacy profile in WM patients, all (n=10) of whom were heavily pre-treated/refractory to BTK inhibitors. Per management, participants treated with MB-106 achieved an overall response rate (ORR) of 90%, including three complete responses (CR) and six partial responses. The last patient achieved stable disease. One of the patients who achieved CR remains in remission at 31 months, with an immunoglobulin M (IgM) level that declined rapidly to the normal range after treatment with MB-106. The therapy also achieved a favorable safety profile in these patients. Mustang Bio presented the above results at the European Hematology Association 2024 Hybrid Congress (EHA2024). Post the above announcement, the share price rose nearly 477% on Jun 17. Investors were impressed with the safety and efficacy results, as it showed that treatment with MB-106 has the potential to improve the quality of responses
Show less
Read more
Impact Snapshot
Event Time:
MBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MBIO alerts
High impacting Mustang Bio, Inc. news events
Weekly update
A roundup of the hottest topics
MBIO
News
- Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewswire
- Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules [Yahoo! Finance]Yahoo! Finance
- Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewswire
- Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy [Yahoo! Finance]Yahoo! Finance
- Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T TherapyGlobeNewswire
MBIO
Earnings
- 11/14/23 - Beat
MBIO
Sec Filings
- 8/16/24 - Form 424B5
- 8/13/24 - Form 10-Q
- 7/30/24 - Form EFFECT
- MBIO's page on the SEC website